Op-ED Links Biopharmaceuticals controversy with FTA Implementation and Special 301 Report
In this Op-Ed piece in El Espectador, Rodrigo Lara states that regulation of biopharmaceuticals in Colombia will be heavily influenced by the interests of pharmaceutical companies, the FTA implementation process and USTR’s Special 301 Report. While provocative, the text misleads the reader to understand that Phrma’s input into the Special 301 report (http://bit.ly/dbb5P3) are the same as the recommendations issued through USTR’s final report (http://bit.ly/xp3C5f) . Article: http://bit.ly/zqWVSN
Discussion around regulating Biotech Drugs in Colombia
Article presents the positions of the four key players in the discussion to open the Colombian market to generic biotech: Multinational pharmceutical companies, local pharmaceutical companies, patient associations, national medicine academy, medical associations, Government of Colombia. http://bit.ly/yggYLs
First Post: Rodrigo Lara says biopharmaceuticals regulation will have an impact on FTA implementation
Fedesarrollo study shines light on overpricing and potential regulation of biopharmaceutical drugs http://bit.ly/AgpjzQ
